An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer

PURPOSE: Pegfilgrastim is a widely used long-acting granulocyte colony-stimulating factor (G-CSF) that prevents febrile neutropenia (FN) in patients with breast cancer receiving chemotherapy. This study aimed to evaluate the incidence of chemotherapy-related FN events and other adverse events (AEs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Anbok, Kang, Taewoo, Kang, Su Hwan, Park, Woo-Chan, Lim, Woosung, Chang, Myung-Chul, Kim, Hyun Yul, Song, Jeong-yoon, Lee, Jihyoun, Byun, Kyung Do, Kim, Hyun-Ah, Son, Gil Soo, Kim, Ju-Yeon, Oh, Se Jeong, Chung, Min Sung, Choi, Young Jin, Shin, Hyuk-Jai, Baek, Jong Min, Yoo, Youngbum, Um, Eunhae, Choi, Jin Hyuk, Kwak, Beom Seok, Park, Min Ho, Lee, Suok Hyun, Kim, Cheol Seung, Lee, Ilkyun, Kim, Je-Ryong, Lee, Han Shin, Lim, Cheol Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568407/
https://www.ncbi.nlm.nih.gov/pubmed/37802015
http://dx.doi.org/10.1016/j.breast.2023.103585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568407/
https://www.ncbi.nlm.nih.gov/pubmed/37802015
http://dx.doi.org/10.1016/j.breast.2023.103585

Ejemplares similares